With the conclusion of Q4 2022 results reporting period, we look back at the overall 2022 financial performance for European Pharma under our coverage and how they fared against consensus estimates, as well as the outlook for 2023.
Fundamental, Research
European Pharma: Top Picks as Growth Slows; New Launches and Core Products are Key
09 March 2023
Summary
Want to learn more? Download the Report.
Solutions
Fundamental Equity Research
Gain a comprehensive view of global themes, industries, and companies.
Public Policy & Legal Research
Identify opportunity and risk driven by public policy and the courts.
Forensic Accounting Research
Understand implications of public company financial reporting.Related Insights
Health Care REITs Poised for Healthy Returns
The aging US population and increasing healthcare expenditures...
Read more